Renaissance Technologies
SUPN icon

Renaissance Technologies’s Supernus Pharmaceuticals SUPN Stock Holding History

Renaissance Technologies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.1M Sell
1,705,222
-27,300
-2% -$1.39M 0.14% 167
2025
Q4 		$86.1M Sell
1,732,522
-8,100
-0.5% -$394K 0.13% 173
2025
Q3 		$83.2M Buy
1,740,622
+85,300
+5% +$3.44M 0.11% 208
2025
Q2 		$52.2M Buy
1,655,322
+69,600
+4% +$2.23M 0.07% 326
2025
Q1 		$51.9M Sell
1,585,722
-13,000
-0.8% -$461K 0.08% 308
2024
Q4 		$57.8M Sell
1,598,722
-129,900
-8% -$4.57M 0.09% 276
2024
Q3 		$53.9M Buy
1,728,622
+43,500
+3% +$1.36M 0.08% 296
2024
Q2 		$45.1M Buy
1,685,122
+351,900
+26% +$10.2M 0.08% 322
2024
Q1 		$45.5M Sell
1,333,222
-45,200
-3% -$1.35M 0.07% 329
2023
Q4 		$39.9M Sell
1,378,422
-60,000
-4% -$1.59M 0.06% 361
2023
Q3 		$39.7M Sell
1,438,422
-57,900
-4% -$1.76M 0.07% 329
2023
Q2 		$45M Buy
1,496,322
+102,800
+7% +$3.6M 0.06% 346
2023
Q1 		$50.5M Buy
1,393,522
+133,000
+11% +$5.11M 0.07% 345
2022
Q4 		$45M Sell
1,260,522
-19,700
-2% -$685K 0.06% 370
2022
Q3 		$43.3M Sell
1,280,222
-116,800
-8% -$3.8M 0.06% 364
2022
Q2 		$40.4M Buy
1,397,022
+153,500
+12% +$4.4M 0.05% 429
2022
Q1 		$40.2M Buy
1,243,522
+4,400
+0.4% +$135K 0.05% 423
2021
Q4 		$36.1M Sell
1,239,122
-149,500
-11% -$4.54M 0.05% 434
2021
Q3 		$37M Sell
1,388,622
-127,600
-8% -$3.42M 0.05% 403
2021
Q2 		$46.7M Sell
1,516,222
-244,000
-14% -$7.48M 0.06% 352
2021
Q1 		$46.1M Sell
1,760,222
-89,300
-5% -$2.5M 0.06% 376
2020
Q4 		$46.5M Sell
1,849,522
-18,978
-1% -$408K 0.05% 375
2020
Q3 		$38.9M Buy
1,868,500
+275,700
+17% +$6.26M 0.04% 459
2020
Q2 		$37.8M Buy
1,592,800
+690,600
+77% +$15.3M 0.03% 512
2020
Q1 		$16.2M Sell
902,200
-18,900
-2% -$397K 0.02% 885
2019
Q4 		$21.8M Buy
921,100
+358,900
+64% +$8.72M 0.02% 955
2019
Q3 		$15.4M Sell
562,200
-42,000
-7% -$1.24M 0.01% 1109
2019
Q2 		$20M Buy
604,200
+141,900
+31% +$4.86M 0.02% 964
2019
Q1 		$16.2M Buy
462,300
+118,800
+35% +$4.42M 0.01% 1087
2018
Q4 		$11.4M Sell
343,500
-124,400
-27% -$5.35M 0.01% 1225
2018
Q3 		$23.6M Sell
467,900
-416,790
-47% -$20.6M 0.02% 832
2018
Q2 		$52.9M Buy
884,690
+580,990
+191% +$30.1M 0.06% 419
2018
Q1 		$13.9M Buy
303,700
+277,600
+1,064% +$11.6M 0.02% 1162
2017
Q4 		$1.04M Buy
+26,100
New +$1.03M ﹤0.01% 2647
2015
Q4 		– Sell
-125,100
Closed -$1.75M – 3419
2015
Q3 		$1.75M Buy
125,100
+10,100
+9% +$188K ﹤0.01% 2076
2015
Q2 		$1.95M Buy
+115,000
New +$1.64M ﹤0.01% 2076
2015
Q1 		– Sell
-157,049
Closed -$1.3M – 3337
2014
Q4 		$1.3M Buy
157,049
+120,349
+328% +$1.01M ﹤0.01% 2002
2014
Q3 		$319K Buy
+36,700
New +$331K ﹤0.01% 2452

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's SUPN Position: Q1 2026 in Review

Renaissance Technologies reduced its Supernus Pharmaceuticals (SUPN) stake by 1.6% in Q1 2026, selling an estimated $1.39M and leaving 1,705,222 shares worth $88.1M. The position accounts for 0.14% of the portfolio, ranked #167.

Renaissance Technologies first reported a position in SUPN in Q3 2014 and has held it in 38 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Renaissance Technologies held 1,705,222 shares of Supernus Pharmaceuticals worth $88.1M as of Q1 2026.
  • Renaissance Technologies sold 27,300 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.39M.
  • Supernus Pharmaceuticals made up 0.14% of Renaissance Technologies's portfolio in Q1 2026, its #167 holding.
  • Renaissance Technologies first reported a position in Supernus Pharmaceuticals in Q3 2014 and has held it in 38 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.